John F. Lyons

6.0k citations

76 papers · 4.7k · 2 hit papers · h-index 33

Impact in

Hematology top 1%
- Acute Myeloid Leukemia Research
Oncology top 2%
- Cancer-related Molecular Pathways

Papers in

Hematology 16
- Acute Myeloid Leukemia Research 10
- Chronic Myeloid Leukemia Treatments 7
Genetics 11
- Chronic Lymphocytic Leukemia Research 8

Co-authors: Kurt Grünewald (3 shared papers)Hans Georg Feichtinger (4 shared papers)Gideon E. Bollag (2 shared papers)Orlo H. Clark (2 shared papers)Frank P. McCormick (2 shared papers)Henry R. Bourne (2 shared papers)Barbara Hibner (2 shared papers)S M Wilhelm (1 shared paper)
Journals: Blood (15 papers)Molecular Cancer Therapeutics (7 papers)British Journal of Dermatology (4 papers)Clinical Cancer Research (4 papers)Cancer Research (2 papers)
Partner nations: United States Germany United Kingdom

In The Last Decade

John F. Lyons

76 papers receiving 4.5k citations

John F. Lyons's Hit Papers

align trajectories log scale

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies 2003 · 684 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2003 Blood
1990 Science

Peers

Countries citing papers authored by John F. Lyons

Since Specialization

Citations

This map shows the geographic impact of John F. Lyons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Lyons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Lyons more than expected).

Fields of papers citing papers by John F. Lyons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. Lyons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Lyons. The network helps show where John F. Lyons may publish in the future.

Co-authors

The 25 scholars most cited alongside John F. Lyons, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John F. Lyons Line = papers co-authored together John F. Lyons links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 76 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Two G Protein Oncogenes in Human Endocrine Tumors Science ·John F. Lyons, Claudia A. Landis, Griffith Harsh, Lucia Vallar, Kurt Grünewald, Hans Georg Feichtinger, Quan‐Yang Duh, Orlo H. Clark, Ernest S. Kawasaki, Henry R. Bourne, Frank P. McCormick Hit paper breakdown →	1990	907
2	Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies Blood ·Jean‐Pierre J. Issa, Guillermo Garcia‐Manero, Francis Joseph Giles, Rajan K. Mannari, Deborah Ann Thomas, Stefan H Faderl, Emel Bayar, John F. Lyons, Craig S. Rosenfeld, Jörge E. Cortes, H Kantarjian Hit paper breakdown →	2003	684
3	Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. PubMed ·M. Jane Arboleda, John F. Lyons, Fairooz F. Kabbinavar, Mark Robert Bray, Bryan E. Snow, Raul Ayala, Mordechai Danino, Beth Y. Karlan, Dennis J. Slamon	2003	363
4	Discovery of a novel Raf kinase inhibitor. Endocrine Related Cancer ·John F. Lyons, S M Wilhelm, Barbara Hibner, Gideon E. Bollag	2001	345
5	High frequency of Ki‐ras codon 12 mutations in pancreatic adenocarcinomas International Journal of Cancer ·Kurt Grünewald, John F. Lyons, Anja Fröhlich, Hans Georg Feichtinger, Richard A. Weger, Gerhard P. Schwab, Johannes W.G. Janssen, Claus Rainer Bartram	1989	262
6	Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines Molecular Cancer Therapeutics ·Matthew S. Squires, Ruth E. Feltell, Nicola G. Wallis, Edward J. Lewis, Donna-Michelle Smith, David M. Cross, John F. Lyons, Neil T. Thompson	2009	141
7	Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes Blood ·John F. Lyons, JW Janssen, CR Bartram, Mark Layton, GJ Mufti	1988	106
8	An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations Clinical Cancer Research ·Nicholas Pulliam, Fang Fang, Ali Özeş, Jessica Tang, Adeoluwa Adewuyi, Harold N Keer, John F. Lyons, Stephen B. Baylin, Daniela Matei, Harikrishna Nakshatri, Feyruz Virgilia Rassool, Kathy D. Miller, Kenneth P. Nephew	2018	102
9	The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer Clinical Cancer Research ·Fang Fang, Joanne M. Munck, Jessica Tang, Pietro Taverna, Yinu Wang, David F. Miller, Jay M. Pilrose, Gavin S. Choy, Mohammad A. Azab, Katherine S. Pawelczak, Pamela S. VanderVere-Carozza, Michael A. Wagner, John F. Lyons, Daniela Matei, John J. Turchi, Kenneth P. Nephew	2014	82
10	Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications World Journal of Surgery ·Peter Erich Goretzki, John F. Lyons, Sandrina Stacy‐Phipps, Werner Rosenau, Michael J. Demeure, Orlo H. Clark, Frank P. McCormick, H. D. Röher, Henry R. Bourne	1992	79
11	First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors Clinical Cancer Research ·G D Shapiro, Eunice Lee Kwak, Bruce Jeffrey Dezube, Murray Yule, John Ayrton, John F. Lyons, Daruka Mahadevan	2014	77
12	Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach Bioorganic & Medicinal Chemistry Letters ·Roger A. Smith, James A. Barbosa, Cheri L. Blum, Mark A. Bobko, Yolanda Caringal, Robert D. Dally, Jeffrey S. Johnson, Michael Katz, Nancy Kennure, Jill E. Kingery-Wood, Wendy W.L. Lee, Timothy B. Lowinger, John F. Lyons, Vivienne Marsh, Daniel H. Rogers, Stephen G. Swartz, Tracy L. Walling, Hanno Wild	2001	76
13	Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models Molecular Cancer Therapeutics ·Tomoko Smyth, Kim H.T. Paraiso, Keisha Hearn, Ana M. Rodríguez-López, Joanne M. Munck, Hans Eirik Haarberg, Vernon K. Sondak, Neil T. Thompson, Mohammad A. Azab, John F. Lyons, Keiran S.M. Smalley, Nicola G. Wallis	2014	75
14	The heat shock protein 90 inhibitor, AT 13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer Cancer Science ·Brent L. Graham, Jayne E. Curry, Tomoko Smyth, Lynsey Fazal, Ruth E. Feltell, Isobel L. Harada, Joe Coyle, Brian Williams, Matthias Reule, Hayley C. Angove, David M. Cross, John F. Lyons, Nicola G. Wallis, Neil T. Thompson	2011	73
15	Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma Epigenetics ·Simone Jueliger, John F. Lyons, Sara Cannito, Illar Pata, Pille Pata, Marianna Shkolnaya, Oriana Lo Re, Marion Peyrou, Francesc Villarroya, Valerio Pazienza, F. Rappa, Francesco Cappello, Mohammad A. Azab, Pietro Taverna, Manlio Vinciguerra	2016	71
16	Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells Blood ·Ruriko Tanaka, Matthew S. Squires, Shinya H Kimura, Asumi Yokota, Rina Nagao, Takahiro Yamauchi, Miki Takeuchi, Hisayuki Yao, Matthias Reule, Tomoko Smyth, John F. Lyons, Neil T. Thompson, Eishi Ashihara, Oliver Gerhard Ottmann, Taira Maekawa	2010	58
17	Detection of enteroviral ribonucleic acid in myocardial biopsies from patients with idiopathic dilated cardiomyopathy by polymerase chain reaction American Heart Journal ·Andrea Schwaiger, Florian Umlauft, Katharina Weyrer, Clara Larcher, John F. Lyons, V. Mühlberger, Otto Dietze, Kurt Grünewald	1993	55
18	AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth Molecular Cancer Therapeutics ·Kyla M. Grimshaw, Lisa-Jane K. Hunter, Timothy Anthony Yap, Simon P. Heaton, Mike I. Walton, Steven J. Woodhead, Lynsey Fazal, Matthias Reule, Thomas G. Davies, Lisa C. A. Seavers, Victoria Lock, John F. Lyons, Neil T. Thompson, Paul Workman, Michelle Dawn Garrett	2010	55
19	ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth Molecular Cancer Therapeutics ·George A. Ward, Edward J. Lewis, Jong Sook Ahn, Christopher N. Johnson, John F. Lyons, Vanessa Martins, Joanne M. Munck, Sharna J. Rich, Tomoko Smyth, Neil T. Thompson, Pamela A. Williams, Nicola E. Wilsher, Nicola G. Wallis, Gianni Chessari	2018	54
20	A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies Annals of Oncology ·Hendrik‐Tobias Arkenau, Ruth Plummer, L. Rhoda Molife, D. Olmos, Timothy Anthony Yap, Matthew S. Squires, Sara C. Lewis, Victoria Lock, Murray Yule, John F. Lyons, Hilary Calvert, Ian Robert Judson	2011	54

About John F. Lyons

John F. Lyons is a scholar working on Hematology, Genetics, Molecular Biology, Cell Biology and Oncology, having authored 76 papers that have together received 4.7k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (11 papers), Microtubule and mitosis dynamics (11 papers), Acute Myeloid Leukemia Research (10 papers), Chronic Lymphocytic Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (7 papers), Protein Degradation and Inhibitors (6 papers), Melanoma and MAPK Pathways (6 papers) and Cancer Mechanisms and Therapy (5 papers). The work is most often cited by research in Hematology (630 citations), Oncology (1.2k citations), Molecular Biology (2.7k citations), Cancer Research (483 citations) and Genetics (329 citations). John F. Lyons has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Kurt Grünewald, Hans Georg Feichtinger, Gideon E. Bollag, Orlo H. Clark, Frank P. McCormick, Henry R. Bourne, Barbara Hibner, S M Wilhelm, Griffith Harsh and Claudia A. Landis. Their work appears in journals such as Blood, Molecular Cancer Therapeutics, British Journal of Dermatology, Clinical Cancer Research and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

John F. Lyons

Impact in

Papers in i

In The Last Decade

John F. Lyons

John F. Lyons's Hit Papers

Peers

Countries citing papers authored by John F. Lyons

Fields of papers citing papers by John F. Lyons

All Works

About John F. Lyons

Explore authors with similar magnitude of impact

Papers in